Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.

Publikation

Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.

Wissenschaftlicher Artikel/Review - 29.04.2022

Zeitlberger A M, Putora Paul Martin, Hofer S, Schucht P, Migliorini D, Hottinger A F, Roelcke U, Läubli H, Spina P, Bozinov Oliver, Weller M, Neidert M, Hundsberger Thomas

Zitation

Zeitlberger A, Putora P, Hofer S, Schucht P, Migliorini D, Hottinger A, Roelcke U, Läubli H, Spina P, Bozinov O, Weller M, Neidert M, Hundsberger T. Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis. J Neurooncol 2022; 158:359-367.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

J Neurooncol 2022; 158

Veröffentlichungsdatum

29.04.2022

eISSN (Online)

1573-7373

Seiten

359-367

Kurzbeschreibung/Zielsetzung

Glioblastoma is the most common malignant primary brain tumour in adults and driven by various genomic alterations. Next generation sequencing (NGS) provides timely information about the genetic landscape of tumours and might detect targetable mutations. To date, differences exist in the application and NGS assays used as it remains unclear to what extent these variants may affect clinical decision making. In this survey-based study, we investigated the use of NGS in adult patients with glioblastoma in Switzerland.